# Suzhou Ribo Life Science Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-ribo-life-science-co

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.ribolia.com
- Total disclosed funding: $222M
- Latest round: Series E (Jul 21, 2025)
- Investors on record: 25

## About

Based in Suzhou, China and founded in 2007, Suzhou Ribo Life Science Co., Ltd. is a biopharmaceutical engaged in the research and development of RNAi technologies and oligonucleotide therapeutics. In August 2020, the company received the approval of clinical trials for new drug treatment of metastatic prostate cancer. In February 2022, it established an international R&D center in Gothenburg, Sweden.

In August 2020, Suzhou Ribo Life Science Co., Ltd. was converted into a joint stock company. In January 2026, the company raised HKD 1.83 billion in an IPO, selling 31.61 million shares at HKD 57.97 apiece on the Hong Kong Exchanges and Clearing (HKEX) under the ticker "6938".

Suzhou Ribo Life Science Co., Ltd. specializes in developing oligonucleotide drugs based on RNA interference (RNAi) technology, focusing on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The company's core products include RBD4059, an siRNA (small interfering RNA) drug that targets thrombotic diseases; RBD1016, an siRNA drug for patients with chronic hepatitis B Virus (“HBV”) infection, and other drug candidates for hereditary angioedema and inflammatory diseases.

The company generates revenue from developing and commercializing oligonucleotide drugs globally.

## Funding rounds

- Series E, Jul 21, 2025, $28M — Mingxin Capital, Panlin Capital, Everest VC, Kunshan Hi-Tech Venture Capital
- Series E, Jul 29, 2022, $40M — Panlin Capital, Trinity Innovation Fund
- Series C, Apr 3, 2020, $66M — China International Capital Corporation, Everest VC, China Reform Holdings, Hongtao Fund Management, FTZ Fund, Sinopharm-CICC Capital, Hengxu Capital, GL Ventures, Shenzhen Co-way Capital
- Series C, Dec 5, 2019, $29M — Legend Capital, InnoSpring, Panlin Capital, CS Capital, BOCG, Kunshan Hanyang Investment
- Series B, Dec 1, 2017 — InnoSpring
- Series B, Mar 17, 2017, $39M — Legend Capital, Lotus Lake Capital, CR Capital, Panlin Capital, CS Capital, ZHYT Investment Management, Jiyuan Capital
- Series A, Sep 28, 2015, $20M — Legend Capital, Legend Star, V Star Capital, Jiyuan Capital, Kunshan RNAi Institute

## Investors

- Legend Capital — Series A, Series B, Series C
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- V Star Capital (https://capitalatlas.ai/funds/v-star-capital) — Series A
- Jiyuan Capital (https://capitalatlas.ai/funds/jiyuan-capital) — Series A, Series B
- Kunshan RNAi Institute — Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series B
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series B, Series C, Series E
- CS Capital — Series B, Series C
- ZHYT Investment Management (https://capitalatlas.ai/funds/zhyt-investment-management) — Series B
- InnoSpring (https://capitalatlas.ai/funds/innospring) — Series B, Series C
- BOCG (https://capitalatlas.ai/funds/bocg) — Series C
- Kunshan Hanyang Investment (https://capitalatlas.ai/funds/kunshan-hanyang-investment) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series C, Series E
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series C
- Hongtao Fund Management (https://capitalatlas.ai/funds/hongtao-fund-management) — Series C
- FTZ Fund (https://capitalatlas.ai/funds/ftz-fund) — Series C
- Sinopharm-CICC Capital (https://capitalatlas.ai/funds/sinopharm-cicc-capital) — Series C
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- Shenzhen Co-way Capital (https://capitalatlas.ai/funds/shenzhen-co-way-capital) — Series C
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series E
- Mingxin Capital (https://capitalatlas.ai/funds/mingxin-capital) — Series E
- Kunshan Hi-Tech Venture Capital — Series E